cimetidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histamine-H2-receptor antagonists, cimetidine derivatives 645 51481-61-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cimetidine
  • tagamet
  • tametin
  • ulcedin
  • ulcedine
  • ulcerex
  • ulcerfen
  • cimetidine hydrochloride
  • cimetidine HCl
A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
  • Molecular weight: 252.34
  • Formula: C10H16N6S
  • CLOGP: 0.38
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 88.89
  • ALOGS: -3.16
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g O
0.80 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 6.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 62 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 158.51 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.78 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 16, 1977 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Body tinea 158.30 13.74 44 15061 1841 63472076
Urine abnormality 149.54 13.74 58 15047 6961 63466956
Inhibitory drug interaction 140.36 13.74 44 15061 2805 63471112
Infection susceptibility increased 131.20 13.74 44 15061 3477 63470440
Urine leukocyte esterase positive 118.75 13.74 41 15064 3538 63470379
Glucose tolerance impaired 107.78 13.74 45 15060 6532 63467385
Poor quality sleep 97.11 13.74 60 15045 19875 63454042
Lymphocyte count decreased 94.28 13.74 69 15036 30188 63443729
Purpura 89.90 13.74 47 15058 11338 63462579
Hyperlipidaemia 85.54 13.74 55 15050 19516 63454401
Bone density decreased 78.93 13.74 47 15058 14565 63459352
Impaired quality of life 78.83 13.74 46 15059 13737 63460180
Culture urine positive 73.36 13.74 29 15076 3658 63470259
Urine ketone body present 69.05 13.74 25 15080 2478 63471439
Impaired work ability 66.39 13.74 45 15060 17430 63456487
Drug intolerance 61.01 13.74 3 15102 308658 63165259
Blood urine present 60.11 13.74 40 15065 15029 63458888
Chronic kidney disease 57.23 13.74 62 15043 45336 63428581
Oral herpes 56.47 13.74 48 15057 26026 63447891
Skin disorder 51.35 13.74 48 15057 29459 63444458
Anaphylactoid reaction 49.57 13.74 22 15083 3701 63470216
Joint swelling 43.65 13.74 12 15093 327654 63146263
Erythema 41.32 13.74 113 14992 175638 63298279
Neutrophil count increased 41.16 13.74 33 15072 16494 63457423
Cataract 39.87 13.74 58 15047 56995 63416922
Cellulitis 36.52 13.74 68 15037 81890 63392027
Rheumatoid arthritis 36.31 13.74 8 15097 253811 63220106
Torsade de pointes 36.14 13.74 28 15077 13323 63460594
Keratitis 35.48 13.74 17 15088 3405 63470512
Hypertension 34.80 13.74 145 14960 279158 63194759
Band sensation 32.88 13.74 11 15094 862 63473055
Bacterial test positive 31.10 13.74 18 15087 5289 63468628
Specific gravity urine decreased 30.03 13.74 10 15095 772 63473145
Insomnia 29.38 13.74 115 14990 215137 63258780
Tri-iodothyronine free decreased 29.22 13.74 8 15097 316 63473601
Creatinine urine decreased 27.99 13.74 7 15098 193 63473724
Therapeutic product effect decreased 27.80 13.74 6 15099 193181 63280736
Product use issue 27.66 13.74 9 15096 220511 63253406
Arthropathy 27.05 13.74 11 15094 234781 63239136
Red cell distribution width increased 26.18 13.74 21 15084 10503 63463414
Circulatory collapse 25.97 13.74 29 15076 21909 63452008
Wound 25.79 13.74 4 15101 163259 63310658
Herpes zoster 25.63 13.74 59 15046 82403 63391514
Infusion site scar 25.42 13.74 8 15097 516 63473401
Contraindicated product administered 25.40 13.74 10 15095 217638 63256279
Urticaria 24.60 13.74 91 15014 165711 63308206
Infusion site discomfort 24.04 13.74 10 15095 1436 63472481
Systemic lupus erythematosus 23.72 13.74 10 15095 208908 63265009
Drug ineffective 23.65 13.74 149 14956 1044616 62429301
Electrocardiogram T wave amplitude decreased 23.56 13.74 7 15098 372 63473545
Product dose omission issue 22.46 13.74 14 15091 234299 63239618
Red blood cells urine positive 22.12 13.74 12 15093 3114 63470803
Blood thyroid stimulating hormone increased 21.48 13.74 16 15089 7178 63466739
Peripheral swelling 21.48 13.74 19 15086 265923 63207994
Protein urine present 21.45 13.74 15 15090 6105 63467812
Maternal exposure during pregnancy 21.30 13.74 13 15092 220049 63253868
Death 21.21 13.74 157 14948 374224 63099693
White blood cell count decreased 21.18 13.74 77 15028 139027 63334890
Anxiety 21.13 13.74 105 15000 217436 63256481
Red blood cell count decreased 21.01 13.74 36 15069 40609 63433308
Myelosuppression 20.94 13.74 27 15078 23676 63450241
Alanine aminotransferase increased 20.76 13.74 63 15042 103707 63370210
Basophil count increased 20.70 13.74 8 15097 949 63472968
Urobilinogen urine increased 20.62 13.74 6 15099 296 63473621
Intentional product use issue 20.50 13.74 3 15102 127889 63346028
Nitrite urine present 19.87 13.74 8 15097 1058 63472859
Flushing 19.36 13.74 50 15055 75037 63398880
Palmar-plantar erythrodysaesthesia syndrome 18.45 13.74 25 15080 22990 63450927
Hepatic enzyme increased 18.16 13.74 13 15092 202315 63271602
Food interaction 18.11 13.74 7 15098 831 63473086
Blood creatinine decreased 18.07 13.74 13 15092 5532 63468385
Infusion site rash 17.96 13.74 9 15096 1985 63471932
Chromaturia 17.93 13.74 21 15084 16696 63457221
Abdominal discomfort 17.47 13.74 31 15074 320854 63153063
Monocyte count decreased 17.31 13.74 9 15096 2144 63471773
Lower respiratory tract infection 17.30 13.74 5 15100 132302 63341615
Pancreatitis acute 16.67 13.74 26 15079 27140 63446777
White blood cells urine positive 16.59 13.74 12 15093 5146 63468771
Thyroid cyst 16.51 13.74 6 15099 601 63473316
Arthralgia 16.28 13.74 75 15030 569635 62904282
QRS axis abnormal 16.24 13.74 7 15098 1098 63472819
Bone marrow infiltration 15.81 13.74 6 15099 678 63473239
Platelet count decreased 15.78 13.74 62 15043 116060 63357857
Infusion site warmth 15.78 13.74 8 15097 1810 63472107
Glucose urine present 15.41 13.74 6 15099 726 63473191
Musculoskeletal stiffness 15.13 13.74 13 15092 184605 63289312
Visual acuity reduced 14.97 13.74 22 15083 21804 63452113
pH urine increased 14.88 13.74 5 15100 397 63473520
Red cell distribution width decreased 14.81 13.74 8 15097 2057 63471860
Anion gap decreased 14.68 13.74 5 15100 414 63473503
Immune thrombocytopenia 14.33 13.74 15 15090 10541 63463376
White blood cell count increased 14.27 13.74 34 15071 48527 63425390
Product use in unapproved indication 14.20 13.74 13 15092 179067 63294850
Drug exposure before pregnancy 14.00 13.74 6 15099 928 63472989
Haematocrit increased 13.92 13.74 8 15097 2318 63471599
Eosinophil count increased 13.89 13.74 15 15090 10913 63463004
Swelling 13.76 13.74 28 15077 275350 63198567

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 35.13 16.25 39 5888 41171 34909833
Renal injury 22.19 16.25 17 5910 11178 34939826
Mucosal erosion 20.38 16.25 7 5920 837 34950167
Palmar-plantar erythrodysaesthesia syndrome 18.06 16.25 18 5909 16777 34934227
Peptic ulcer 18.01 16.25 9 5918 2774 34948230
Decreased appetite 16.75 16.25 64 5863 166328 34784676

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urine abnormality 158.78 13.37 62 17566 8157 79718603
Body tinea 157.55 13.37 43 17585 1811 79724949
Inhibitory drug interaction 128.05 13.37 45 17583 4408 79722352
Infection susceptibility increased 128.01 13.37 43 17585 3678 79723082
Urine leukocyte esterase positive 116.33 13.37 41 17587 4050 79722710
Lymphocyte count decreased 99.57 13.37 83 17545 47206 79679554
Glucose tolerance impaired 98.80 13.37 44 17584 8040 79718720
Poor quality sleep 93.93 13.37 60 17568 22662 79704098
Bone density decreased 80.61 13.37 45 17583 13302 79713458
Hyperlipidaemia 77.13 13.37 56 17572 26037 79700723
Urine ketone body present 76.37 13.37 29 17599 3536 79723224
Impaired quality of life 74.83 13.37 44 17584 14342 79712418
Purpura 74.41 13.37 49 17579 19478 79707282
Culture urine positive 70.23 13.37 29 17599 4406 79722354
Impaired work ability 57.62 13.37 42 17586 19639 79707121
Oral herpes 55.32 13.37 47 17581 27407 79699353
Blood urine present 50.33 13.37 40 17588 21257 79705503
Hypertension 47.60 13.37 171 17457 330821 79395939
Skin disorder 46.78 13.37 47 17581 33896 79692864
Erythema 43.51 13.37 128 17500 223162 79503598
Anaphylactoid reaction 43.23 13.37 22 17606 5400 79721360
Cataract 39.35 13.37 58 17570 62062 79664698
Torsade de pointes 36.75 13.37 32 17596 19280 79707480
Off label use 36.41 13.37 93 17535 907122 78819638
Keratitis 35.81 13.37 18 17610 4304 79722456
Red cell distribution width increased 32.58 13.37 27 17601 15215 79711545
Insomnia 32.14 13.37 123 17505 245047 79481713
Joint swelling 31.83 13.37 12 17616 288634 79438126
Band sensation 30.68 13.37 10 17618 778 79725982
Flushing 30.41 13.37 63 17565 88205 79638555
Urticaria 30.35 13.37 100 17528 185101 79541659
Palmar-plantar erythrodysaesthesia syndrome 30.28 13.37 37 17591 33097 79693663
Specific gravity urine decreased 29.62 13.37 10 17618 868 79725892
Infusion site scar 28.90 13.37 8 17620 355 79726405
Infusion site discomfort 28.69 13.37 11 17617 1376 79725384
Alanine aminotransferase increased 28.64 13.37 90 17538 162480 79564280
Chronic kidney disease 28.63 13.37 52 17576 66102 79660658
Tri-iodothyronine free decreased 28.54 13.37 8 17620 372 79726388
Red blood cell count decreased 27.20 13.37 47 17581 57466 79669294
Bacterial test positive 26.70 13.37 18 17610 7431 79719329
Contusion 25.87 13.37 82 17546 148694 79578066
Monocyte count decreased 25.55 13.37 13 17615 3188 79723572
Haematocrit increased 25.45 13.37 14 17614 4020 79722740
White blood cell count decreased 24.28 13.37 94 17534 188194 79538566
Cellulitis 23.63 13.37 65 17563 108995 79617765
Therapeutic product effect decreased 23.44 13.37 4 17624 163859 79562901
Infusion site rash 23.18 13.37 10 17618 1692 79725068
Neutrophil count increased 22.40 13.37 30 17598 29366 79697394
Peptic ulcer 22.22 13.37 15 17613 6208 79720552
Creatinine urine decreased 21.86 13.37 6 17622 258 79726502
Therapeutic product effect incomplete 21.30 13.37 3 17625 141642 79585118
Basophil count increased 21.03 13.37 9 17619 1494 79725266
Rheumatoid arthritis 20.84 13.37 10 17618 208460 79518300
Herpes zoster 20.68 13.37 56 17572 93027 79633733
Secondary adrenocortical insufficiency 20.51 13.37 11 17617 3003 79723757
Protein urine present 19.73 13.37 17 17611 10095 79716665
Platelet count decreased 19.50 13.37 90 17538 194574 79532186
Ventricular tachycardia 19.47 13.37 34 17594 41901 79684859
Nitrite urine present 19.46 13.37 8 17620 1201 79725559
Mean cell haemoglobin increased 19.42 13.37 12 17616 4273 79722487
Drug ineffective 18.86 13.37 151 17477 1080762 78645998
Gastrooesophageal reflux disease 18.62 13.37 58 17570 104188 79622572
Arthropathy 18.48 13.37 8 17620 177103 79549657
Red cell distribution width decreased 18.40 13.37 9 17619 2029 79724731
Blood thyroid stimulating hormone increased 18.30 13.37 16 17612 9692 79717068
Infusion site warmth 18.03 13.37 8 17620 1447 79725313
White blood cells urine positive 17.86 13.37 13 17615 6062 79720698
Peripheral swelling 17.81 13.37 20 17608 269597 79457163
Product use in unapproved indication 17.17 13.37 18 17610 250341 79476419
Blood creatinine decreased 17.01 13.37 14 17614 7811 79718949
Drug exposure before pregnancy 16.70 13.37 6 17622 626 79726134
Contraindicated product administered 16.62 13.37 7 17621 157531 79569229
Wound 16.26 13.37 3 17625 116176 79610584
Urobilinogen urine increased 16.25 13.37 6 17622 677 79726083
Aspartate aminotransferase increased 16.09 13.37 67 17561 138574 79588186
Bone marrow infiltration 15.73 13.37 6 17622 740 79726020
Electrocardiogram T wave amplitude decreased 15.70 13.37 6 17622 744 79726016
Leukocyturia 15.67 13.37 8 17620 1975 79724785
Product dose omission issue 15.66 13.37 19 17609 247518 79479242
Product use issue 15.64 13.37 14 17614 209808 79516952
Circulatory collapse 15.53 13.37 29 17599 37639 79689121
Eosinophil count increased 15.46 13.37 19 17609 17086 79709674
Red blood cells urine positive 15.46 13.37 11 17617 4952 79721808
Myelosuppression 15.35 13.37 30 17598 40266 79686494
Hepatic function abnormal 15.26 13.37 43 17585 73064 79653696
Thyroid cyst 15.18 13.37 5 17623 402 79726358
Coronary artery disease 15.16 13.37 40 17588 65434 79661326
Anxiety 14.90 13.37 100 17528 248412 79478348
Infusion site pruritus 14.88 13.37 10 17618 4108 79722652
Blood alkaline phosphatase increased 14.84 13.37 39 17589 63625 79663135
pH urine increased 14.67 13.37 5 17623 447 79726313
Mean cell haemoglobin concentration increased 14.62 13.37 6 17622 897 79725863
Mucosal erosion 14.50 13.37 8 17620 2310 79724450
Gamma-glutamyltransferase increased 14.31 13.37 35 17593 54645 79672115
Anaphylactic shock 13.96 13.37 27 17601 35969 79690791
Pericarditis 13.94 13.37 3 17625 104233 79622527
Duodenal ulcer haemorrhage 13.89 13.37 12 17616 7151 79719609
Food interaction 13.84 13.37 7 17621 1695 79725065
Dyspepsia 13.78 13.37 54 17574 108633 79618127
Blood lactate dehydrogenase increased 13.53 13.37 28 17600 39142 79687618

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BA01 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
H2-receptor antagonists
ATC A02BA51 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
H2-receptor antagonists
FDA MoA N0000000151 Histamine H2 Receptor Antagonists
CHEBI has role CHEBI:37961 H2 receptor antagonists
CHEBI has role CHEBI:49201 anti-ulcer drugs
CHEBI has role CHEBI:50183 P450 inhibitors
CHEBI has role CHEBI:60809 adjuvants
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006635 Histamine H2 Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D018377 Neurotransmitter Agents
FDA EPC N0000175784 Histamine-2 Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Heartburn indication 16331000
Upper gastrointestinal hemorrhage indication 37372002
Duodenal ulcer disease indication 51868009 DOID:1724
Zollinger-Ellison syndrome indication 53132006 DOID:0050782
Multiple endocrine adenomas indication 60549007
Indigestion indication 162031009
Gastroesophageal reflux disease indication 235595009 DOID:8534
Systemic mast cell disease indication 397016004 DOID:349
Gastric ulcer indication 397825006 DOID:10808
Upper GI Bleed Prevention indication
Maintenance of Healing Duodenal Ulcer indication
Pancreatic insufficiency off-label use 37992001
Urticaria off-label use 126485001
Prevention of Stress Ulcer off-label use
NSAID-Induced Gastric Ulcer off-label use
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Malignant tumor of stomach contraindication 363349007 DOID:10534




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.83 acidic
pKa2 6.71 Basic
pKa3 0.0 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H2 receptor GPCR ANTAGONIST Kd 6.14 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.16 PDSP
Multidrug and toxin extrusion protein 1 Transporter IC50 5.92 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter INHIBITOR Ki 5.10 IUPHAR
Histamine H2 receptor GPCR Kd 6.58 CHEMBL
Histamine H2 receptor GPCR ANTAGONIST Ki 5.90 IUPHAR

External reference:

IDSource
4018845 VUID
N0000147147 NUI
D00295 KEGG_DRUG
70059-30-2 SECONDARY_CAS_RN
152402 RXNORM
4018844 VANDF
4018845 VANDF
C0008783 UMLSCUI
CHEBI:3699 CHEBI
CHEMBL30 ChEMBL_ID
CHEMBL1201051 ChEMBL_ID
DB00501 DRUGBANK_ID
D002927 MESH_DESCRIPTOR_UI
2756 PUBCHEM_CID
1231 IUPHAR_LIGAND_ID
3765 INN_ID
80061L1WGD UNII
101 MMSL
2261 MMSL
4448 MMSL
4449 MMSL
6098 MMSL
d00140 MMSL
003415 NDDF
004987 NDDF
373541007 SNOMEDCT_US
83051006 SNOMEDCT_US
83532008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8192 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8192 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8192 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8204 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8204 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8204 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8305 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8305 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8305 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
Good Sense Heartburn Relief HUMAN OTC DRUG LABEL 1 0113-0022 TABLET, FILM COATED 200 mg ORAL ANDA 16 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0121-0649 SOLUTION 300 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0121-0649 SOLUTION 300 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0121-1298 SOLUTION 400 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0121-1298 SOLUTION 400 mg ORAL ANDA 15 sections
cimetidineacid reducer HUMAN OTC DRUG LABEL 1 0363-0022 TABLET, FILM COATED 200 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0053 TABLET, FILM COATED 200 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0317 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0372 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0541 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 0440-1282 TABLET 400 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-626 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-627 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-048 TABLET, FILM COATED 300 mg ORAL ANDA 17 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-265 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-372 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 21695-531 TABLET 300 mg ORAL ANDA 14 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 21695-532 TABLET 400 mg ORAL ANDA 14 sections
Good Neighbor Pharmacy Heartburn Relief HUMAN OTC DRUG LABEL 1 24385-111 TABLET, FILM COATED 200 mg ORAL ANDA 16 sections
Acid Reducer HUMAN OTC DRUG LABEL 1 30142-323 TABLET, FILM COATED 200 mg ORAL ANDA 16 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 33261-024 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections